LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, announced that Executive Chairman and Founder, Gabriele Cerrone and the OKYO management team will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York today. The ceremony ...